Detalles de la búsqueda
1.
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
Hematol Oncol
; 40(1): 22-30, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34713465
2.
Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres.
Acta Oncol
; 58(3): 306-312, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30507262
3.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
Blood
; 128(14): 1814-1820, 2016 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27354719
4.
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Biol Blood Marrow Transplant
; 23(3): 428-435, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28039078
5.
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
Blood
; 125(17): 2669-77, 2015 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-25736311
6.
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Br J Haematol
; 175(3): 410-418, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27378674
7.
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Blood
; 123(19): 2953-9, 2014 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24652994
8.
Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study.
Acta Oncol
; 55(6): 774-81, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26824275
9.
Whole body MRI, including diffusion-weighted imaging in follow-up of patients with testicular cancer.
Acta Oncol
; 54(10): 1763-9, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25975210
10.
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
Br J Haematol
; 166(1): 98-108, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24684350
11.
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.
BMC Cancer
; 14: 408, 2014 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-24906441
12.
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.
Haematologica
; 103(11): e541-e543, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29794145
13.
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era.
Clin Genitourin Cancer
; 21(6): e438-e448, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308329
14.
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Br J Haematol
; 158(3): 355-62, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22640180
15.
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).
Blood
; 115(8): 1530-3, 2010 Feb 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-20032504
16.
High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Acta Oncol
; 51(2): 168-76, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22175254
17.
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study.
Eur Urol Open Sci
; 40: 38-45, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35638086
18.
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.
Blood
; 112(7): 2687-93, 2008 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18625886
19.
Minor enantiomer recycling: metal catalyst, organocatalyst and biocatalyst working in concert.
Chemistry
; 15(44): 12107-13, 2009 Nov 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-19768712
20.
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Lancet Haematol
; 5(3): e109-e116, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29396091